TNP-2092 IV / TenNor Therap - LARVOL DELTA

Phase 1, Single-Dose and Multiple-Dose Continuous Intravenous Infusions of TNP-2092 for Injection in Healthy Chinese Participants (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: TenNor Therapeutics Inc.

New P1 trial • Infectious Disease

Absorption, Metabolism, and Excretion Study of [14C]-TNP-2092 (clinicaltrials.gov) - P1 | N=6 | Completed | Sponsor: TenNor Therapeutics Limited | Active, not recruiting ➔ Completed

Trial completion

Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty (clinicaltrials.gov) - P1 | N=13 | Completed | Sponsor: TenNor Therapeutics Limited | Active, not recruiting ➔ Completed | Trial completion date: Dec 2022 ➔ Jun 2022

Trial completion • Trial completion date • Infectious Disease • Orthopedics

Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty (clinicaltrials.gov) - P1; N=13; Active, not recruiting; Sponsor: TenNor Therapeutics Limited; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Infectious Disease • Orthopedics

Absorption, Metabolism, and Excretion Study of [14C]-TNP-2092 (clinicaltrials.gov) - P1; N=6; Active, not recruiting; Sponsor: TenNor Therapeutics Limited; Not yet recruiting ➔ Active, not recruiting; Trial completion date: Dec 2022 ➔ Jun 2022; Trial primary completion date: Jun 2022 ➔ Nov 2021

Clinical • Enrollment closed • Trial completion date • Trial primary completion date

Absorption, Metabolism, and Excretion Study of [14C]-TNP-2092 (clinicaltrials.gov) - P1; N=6; Not yet recruiting; Sponsor: TenNor Therapeutics Limited

Clinical • New P1 trial

Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty (clinicaltrials.gov) - P1; N=16; Recruiting; Sponsor: TenNor Therapeutics Limited; Trial completion date: Nov 2021 ➔ Dec 2022; Trial primary completion date: Jun 2021 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date • Infectious Disease • Orthopedics

Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty (clinicaltrials.gov) - P1; N=16; Recruiting; Sponsor: TenNor Therapeutics Limited; Not yet recruiting ➔ Recruiting; Trial completion date: Jul 2021 ➔ Nov 2021

Clinical • Enrollment open • Trial completion date • Orthopedics

P2_ABSSSI: TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection (clinicaltrials.gov) - P2; N=118; Completed; Sponsor: TenNor Therapeutics Limited; Recruiting ➔ Completed; Trial completion date: Jun 2020 ➔ Sep 2020; Trial primary completion date: Sep 2019 ➔ Sep 2020

Clinical • Trial completion • Trial completion date • Trial primary completion date • Infectious Disease

Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty (clinicaltrials.gov) - P1; N=16; Not yet recruiting; Sponsor: TenNor Therapeutics Limited; Initiation date: Mar 2020 ➔ Dec 2020; Trial primary completion date: Jun 2020 ➔ Jun 2021

Clinical • Trial initiation date • Trial primary completion date • Orthopedics

Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty (clinicaltrials.gov) - P1; N=16; Not yet recruiting; Sponsor: TenNor Therapeutics Limited

Clinical • New P1 trial

P2_ABSSSI: TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection (clinicaltrials.gov) - P2; N=120; Recruiting; Sponsor: TenNor Therapeutics Limited; Trial completion date: Jan 2020 ➔ Jun 2020

Clinical • Trial completion date